為探討膽囊癌患者的免疫狀態(tài)及其對(duì)結(jié)石在膽囊癌發(fā)病機(jī)理中的作用,采用散射濁光計(jì)免疫法檢測(cè)了單純膽囊癌、伴膽石膽囊癌、膽石癥患者和健康人的血清補(bǔ)體和免疫球蛋白水平,并采用雙抗體夾心ELISA法測(cè)定了上述各組血清T淋巴細(xì)胞亞群、膽汁和血清中的白細(xì)胞介素2(IL2)和可溶性白細(xì)胞介素2受體(sIL2R)的水平。結(jié)果顯示,單純膽囊癌及伴膽結(jié)石膽囊癌患者的細(xì)胞免疫受抑制,其CD+4細(xì)胞和IL2水平較正常對(duì)照組低,CD+8細(xì)胞和sIL2R水平明顯增高,且與膽囊癌的臨床分期相關(guān)。膽結(jié)石患者與伴膽結(jié)石膽囊癌相比,其CD+4細(xì)胞、IL2水平較高,CD+8細(xì)胞和sIL2R水平較低。本實(shí)驗(yàn)結(jié)果提示:①膽囊癌患者處于免疫抑制狀態(tài);②在伴膽結(jié)石膽囊癌的發(fā)病過程中,膽結(jié)石作為一種慢性損傷和刺激,促使了CD+4、CD+8細(xì)胞之間的平衡及IL2及其受體之間的平衡失調(diào);③動(dòng)態(tài)檢測(cè)T淋巴細(xì)胞及sIL2R水平可作為判斷膽囊癌病情有價(jià)值的參考指標(biāo)。
引用本文： 焦興元,石景森,高金松,周連鎖. 膽囊癌患者細(xì)胞和體液免疫水平的測(cè)定及其臨床意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 1999, 6(4): 227-229. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | LissoniP,BamiS,RovelliF,etal.Thebiologicalsignificanceofsolubleinterleukin2receptorinsolidtumors.EurJCancer,1990;26(1)∶33. |
| 2. | LeeWJ,ChangKJ,LeeCS,etal.SelectdepressionofTlymphocytesubsetsingastriccancerpatients:animplicationofimmunotherapy.JSurgOncol,1994;55(3)∶165. |
| 3. | ZengZC,TangZY,LiuKD,etal.ObservationofchangesinperipheralTlymphocytesubsetsbyflowcytometryinpatientswithlivercancertreatedwithradioimmunotherapy.NucMedCommun,1995;16(5)∶378. |
| 4. | RebinLA,Nelson.Thesolubleinterleukin2receptor:biology,functionandclinicalapplication.AnnInternMed,1990;113(8)∶619. |
| 5. | ButchAW,ChungCH.Cytokineexpressionbygerminalcentercells.JImmunol,1993;150(1)∶39. |
| 6. | LotzeMT,FinnOJ.Recentadvanceincellularimmunology:implicationsforimmunitytocancer.ImmunolToday,1990;11(4)∶190. |
| 7. | 石景森,周連鎖,王作仁等.830例肝外膽管癌的回顧性研究.中華外科雜志,1997;35(11)∶645. |
| 8. | Rabeneck.Gallstoneandbileductcancer.Gastroenterology,1991;107(10)∶1205. |
| 9. | HensorDE,AlboresSavedraJ,CorleD.Carcinomaofthegallbladder:histologic;stageofdisease,gradeandsurvivedrates.Cancer,1992;70(11)∶1483. |
- 1. LissoniP,BamiS,RovelliF,etal.Thebiologicalsignificanceofsolubleinterleukin2receptorinsolidtumors.EurJCancer,1990;26(1)∶33.
- 2. LeeWJ,ChangKJ,LeeCS,etal.SelectdepressionofTlymphocytesubsetsingastriccancerpatients:animplicationofimmunotherapy.JSurgOncol,1994;55(3)∶165.
- 3. ZengZC,TangZY,LiuKD,etal.ObservationofchangesinperipheralTlymphocytesubsetsbyflowcytometryinpatientswithlivercancertreatedwithradioimmunotherapy.NucMedCommun,1995;16(5)∶378.
- 4. RebinLA,Nelson.Thesolubleinterleukin2receptor:biology,functionandclinicalapplication.AnnInternMed,1990;113(8)∶619.
- 5. ButchAW,ChungCH.Cytokineexpressionbygerminalcentercells.JImmunol,1993;150(1)∶39.
- 6. LotzeMT,FinnOJ.Recentadvanceincellularimmunology:implicationsforimmunitytocancer.ImmunolToday,1990;11(4)∶190.
- 7. 石景森,周連鎖,王作仁等.830例肝外膽管癌的回顧性研究.中華外科雜志,1997;35(11)∶645.
- 8. Rabeneck.Gallstoneandbileductcancer.Gastroenterology,1991;107(10)∶1205.
- 9. HensorDE,AlboresSavedraJ,CorleD.Carcinomaofthegallbladder:histologic;stageofdisease,gradeandsurvivedrates.Cancer,1992;70(11)∶1483.